Compare

Arbutus Biopharma Corp vs Pyxis Oncology, Inc. vs CV Sciences, Inc. vs Palatin Technologies Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearArbutus Biopharma Corp
ABUS
Pyxis Oncology, Inc.
PYXS
CV Sciences, Inc.
CVSI
Palatin Technologies Inc
PTN
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenue$14.08M$13.86M$13.79M$13.19M
Revenue growth (YoY)+128.2%-14.2%-12.2%n/a
Gross marginn/a82.8% (computed)49.0%n/a
Operating margin-271.0%-609.2%-3.4%-65.7%
Net margin-237.9%-574.5%-6.9%-63.5%
Net income-$33.50M-$79.62M-$958.0K-$8.38M
EPS (Diluted)-$0.17-$1.28-$0.01-$2.96
Operating cash flow-$39.64M-$63.50M-$407.0K-$13.53M
Free cash flow-$39.64M-$63.51M-$516.0K-$13.58M
Cash & equivalents$18.01M$15.42Mn/a$7.49M
Total assets$94.62M$91.52M$6.96M$8.52M
Total liabilities$18.04M$38.11M$5.49M$1.84M
Shareholders' equity$76.58M$53.41M$1.47M$6.69M
Return on year-end equity-43.7%-149.1%-65.3%-125.3%
Shares outstanding192.53M62.69M184.26M1.78M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearArbutus Biopharma CorpPyxis Oncology, Inc.CV Sciences, Inc.Palatin Technologies Inc
Latest$14.08M
Ended 2025-12-31
$13.86M
Ended 2025-12-31
$13.79M
Ended 2025-12-31
$13.19M
Ended 2026-06-30
1 year earlier$6.17M
Ended 2024-12-31
$16.15M
Ended 2024-12-31
$15.71M
Ended 2024-12-31
n/a
2 years earlier$18.14M
Ended 2023-12-31
n/a$16.00M
Ended 2023-12-31
n/a
3 years earlier$39.02M
Ended 2022-12-31
n/a$16.20M
Ended 2022-12-31
n/a
4 years earlier$10.99M
Ended 2021-12-31
n/a$20.05M
Ended 2021-12-31
n/a